SYRE SEC Filings, Earnings & Splits

Spyre Therapeutics entered into a Second Amended and Restated Employment Letter Agreement with CEO Cameron Turtle, effective November 2, 2026, setting his base salary at $695,000 per year with a 60% target annual bonus and severance provisions.

Spyre Therapeutics filed a routine Form 8-K cover page with the SEC on November 3, 2026. The filing contains only standard registrant identification and XBRL metadata, with no substantive corporate event disclosed.

An amendment to a Schedule 13D was filed regarding Spyre Therapeutics, Inc. The filing text available consists only of the EDGAR directory listing and does not contain substantive details of the amendment.

Spyre Therapeutics, Inc. entered into an underwriting agreement for a public offering of 4,117,648 shares of common stock, with an option for underwriters to purchase up to an additional 617,647 shares.

Spyre Therapeutics filed a 424B5 prospectus supplement under its existing S-3 shelf registration, indicating a securities offering. The filing text contains only XBRL cover-page metadata with no pricing or share details.

Spyre Therapeutics, Inc. filed a preliminary prospectus supplement (424B5) for an underwritten public offering of common stock, with an underwriters' option to purchase additional shares. The offering price and share count are left blank pending completion.

Paradigm BioCapital entities filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Spyre Therapeutics common shares. The filing is a passive investment disclosure with no stated intent to influence control.

Spyre Therapeutics, Inc. filed a Form 8-K on September 8, 2026, covering standard corporate updates and regulatory compliance information.

Spyre Therapeutics, Inc. filed an 8-K form with the SEC on August 25, 2026, but the filing text only contains directory listings and navigation links, not the actual event details.